Prevention of Venous Thromboembolism in Hip Surgery Patients

Youn-Soo Park; Seung-Jae Lim; Taehun Lee

doi:10.5371/hp.2014.26.1.1

Journal List > Hip Pelvis > v.26(1) > 1082015

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Park, Lim, and Lee: Prevention of Venous Thromboembolism in Hip Surgery Patients

Review Article

Hip & Pelvis 2014; 26(1): 1-6.

Published online: 31 March 2014

DOI: https://doi.org/10.5371/hp.2014.26.1.1

Prevention of Venous Thromboembolism in Hip Surgery Patients

Youn-Soo Park, MD, Seung-Jae Lim, MD, Taehun Lee, MD

Department of Orthopedic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Address reprint request to Youn-Soo Park, MD. Department of Orthopedic Surgery, Samsung Medical Center, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. TEL: +82-2-3410-3504, FAX: +82-2-3410-0061, ysp3504@skku.edu

Received 1 February 2014 Revised 25 February 2014 Accepted 5 March 2014

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The risk for venous thromboembolism (VTE) in total hip arthroplasty and hip fracture surgery is much higher than that of any other surgery. There is a general agreement that prevention of VTE in hip surgery patients is necessary due to concerns regarding symptomatic deep vein thrombosis or fatal pulmonary embolism. Optimal strategies for prevention of VTE include pharmacologic and mechanical approaches; however, the ideal prophylactic regimen has not been identified. Selection of a prophylactic regimen should be balanced between efficacy and safety. This article discusses the different prophylactic options available today for prevention of VTE in hip surgery patients.

Keywords: Hip surgery, Venous thromboembolism, Prevention

Figures and Tables

Table 1

Summary of ACCP Evidence-Based Clinical Practice Guidelines (9th ed)

ACCP: American College of Chest Physicians, THA: total hip arthroplasty, LMWH: low-molecular-weight heparin, VKA: vitamin K antagonist, IPCD: intermittent pneumatic compression device, HFS: hip fracture surgery, LDUH: low-dose unfractionated heparin.

References

1. Blann AD, Lip GY. Venous thromboembolism. BMJ. 2006; 332:215–219.

2. Geerts WH, Bergqvist D, Pineo GF, et al. American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133:6 Suppl. 381S–453S.

3. Leizorovicz A, Turpie AG, Cohen AT, Wong L, Yoo MC, Dans A. SMART Study Group. Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART study. J Thromb Haemost. 2005; 3:28–34.

4. Piovella F, Wang CJ, Lu H, et al. AIDA investigators. Deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. J Thromb Haemost. 2005; 3:2664–2670.

5. Yoo MC, Cho YJ, Ghanem E, Ramteke A, Kim KI. Deep vein thrombosis after total hip arthroplasty in Korean patients and D-dimer as a screening tool. Arch Orthop Trauma Surg. 2009; 129:887–894.

6. Kim YH, Kim JS. The 2007 John Charnley Award. Factors leading to low prevalence of DVT and pulmonary embolism after THA: analysis of genetic and prothrombotic factors. Clin Orthop Relat Res. 2007; 465:33–39.

7. Mont MA, Jacobs JJ. AAOS clinical practice guideline: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Am Acad Orthop Surg. 2011; 19:777–778.

8. Falck-Ytter Y, Francis CW, Johanson NA, et al. American College of Chest Physicians. Prevention of VTE in orthopedic surgery patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141:2 Suppl. e278S–e325S.

9. Park YS. Guideline for the prophylaxis of venous thromboembolism in hip surgery patients. J Korean Orthop Assoc. 2011; 46:95–98.

10. Lieberman JR, Pensak MJ. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am. 2013; 95:1801–1811.

11. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000; 355:1295–1302.

12. Hirsh J, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1992; 102:4 Suppl. 337S–351S.

13. Hirsh J, Levine MN. Low molecular weight heparin. Blood. 1992; 79:1–17.

14. Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med. 2001; 135:858–869.

15. Petitou M, Duchaussoy P, Herbert JM, et al. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Semin Thromb Hemost. 2002; 28:393–402.

16. Kakkar AK, Brenner B, Dahl OE, et al. RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008; 372:31–39.

17. Wilke T, Müller S. Nonadherence in outpatient thromboprophylaxis after major orthopedic surgery: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2010; 10:691–700.

18. Lieberman JR. The new AAOS clinical practice guidelines on venous thromboembolic prophylaxis: how to adapt them to your practice. J Am Acad Orthop Surg. 2011; 19:717–721.

TOOLS

Similar articles